JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Home・Akcijų sąrašas・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.19 -5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.18

Max

0.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.5M -37M
Pardavimai	14M 14M
Pelnas, tenkantis vienai akcijai	-0.111
Pelno marža	-262.996
Darbuotojai	142
EBITDA	10M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+3057.89% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-13M 112M
Ankstesnė atidarymo kaina	5.19
Ankstesnė uždarymo kaina	0.19

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.5207 / 0.7223 Palaikymas ir pasipriešinimas

Sangamo Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-28 23:33; UTC

Karštos akcijos

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026-04-28 23:24; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026-04-28 23:15; UTC

Svarbiausios naujienos

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026-04-28 22:46; UTC

Uždarbis

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026-04-28 22:37; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026-04-28 22:15; UTC

Uždarbis

Svarbiausios naujienos

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026-04-28 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026-04-28 23:19; UTC

Rinkos pokalbiai

Uždarbis

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026-04-28 23:09; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026-04-28 23:03; UTC

Rinkos pokalbiai

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026-04-28 22:51; UTC

Uždarbis

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026-04-28 22:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-28 22:48; UTC

Rinkos pokalbiai

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026-04-28 22:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026-04-28 22:32; UTC

Uždarbis

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026-04-28 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026-04-28 22:22; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026-04-28 22:17; UTC

Rinkos pokalbiai

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026-04-28 22:07; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sangamo Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

3057.89% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 3057.89%

Aukščiausias 10 USD

Žemiausias 2 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sangamo Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Sangamo Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.5207 / 0.7223Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.